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http://dx.doi.org/10.1016/j.stemcr.2016.04.001SUMMARYGeneration of induced pluripotent stem cells (iPSCs) from human urine-derived cells (hUCs) provides a convenient and non-invasive
way to obtain patient-specific iPSCs. However, many isolated hUCs exhibit very poor proliferation and are difficult to reprogram. In
this study, we optimized reprogramming approaches for hUCs with very poor proliferation. We report here that a compound cocktail
containing cyclic pifithrin-a (a P53 inhibitor), A-83-01, CHIR99021, thiazovivin, NaB, and PD0325901 significantly improves the reprog-
ramming efficiency (170-fold more) for hUCs. In addition, we showed that replacement of Matrigel with autologous hUC feeders can
overcome the reprogramming failure due to the massive cell death that occurs during delivery of reprogramming factors. In summary,
we describe improved approaches to enable iPSC generation from hUCs that were otherwise difficult to reprogram, a valuable asset
for banking patient-specific iPSCs.INTRODUCTION
Human induced pluripotent stem cell (iPSC) technology
holds great potential for personalized regenerative medi-
cine, drug discovery, and disease modeling without con-
cerns about ethical issues associated with the human
embryo (Yamanaka, 2009). For the achievement of this
goal it is essential to generate patient-specific iPSCs in a
way that is safe enough for clinical applications, for
example, serum free, integration free, and animal compo-
nents free. To date, several approaches have been published
on the generation of virus-free human iPSCs, for example,
using small molecules (SMs) (Esteban et al., 2010; Hou
et al., 2013; Li et al., 2009; Lin et al., 2009; Mali et al.,
2010; Shi et al., 2008; Yu et al., 2011; Zhu et al., 2010),
non-viral minicircles (Jia et al., 2010), or non-integrating
episomal vectors (Yu et al., 2009). We previously reported
that human urine-derived cells (hUCs) could be reprog-
rammed into iPSCswith higher efficiencies than thewidely
used skin fibroblast, thus providing an easy and non-inva-
sive way to obtain somatic cells for iPSC generation (Zhou
et al., 2011). Moreover, we have shown that hUCs served as
a good source to generate human iPSCs using a non-viral
integration approach from different genetic backgrounds
(Xue et al., 2013). However, in our experience culturing
hUCs from different donors, we found that a significant
number of hUCs exhibited very poor proliferation (Tables
1 and 2), and thus were problematic for further iPSC gener-
ation. However, reprogramming these poorly proliferating
hUCs is usually necessary for banking human iPSC lines
from different donors.Stem
This is an open access article under the CMany SMs have been reported to facilitate reprogram-
ming. For example, sodium butyrate (N, NaB), a histone
deacetylase (HDAC) inhibitor, greatly improved reprog-
ramming efficiency by upregulating epigenetic remodeling
and pluripotency-associated genes (Mali et al., 2010; Zhang
and Wu, 2013). In another study, Yu et al. (2011) reported
that an SM cocktail containing MEK inhibitor PD0325901
(PD), GSK3b inhibitor CHIR99021 (C, Chir), transforming
growth factor b (TGF-b)/Activin/Nodal receptor inhibitor
A-83-01 (A), ROCK inhibitor HA-100, and human leukemia
inhibitory factor (hLIF), facilitates iPSC generation from
human neonatal foreskin fibroblasts. Also, Chir was used
to promote iPSC generation fromhumanprimary keratino-
cytes (Li et al., 2009). A summary of these SMs is presented
in Table 3.
In addition, reprogramming factors OSKM have been
shown to trigger cell senescence by upregulating P53,
P16INK4a, and P21CIP1 (Banito et al., 2009). P53-mediated
cell senescence has been known as a barrier to reprogram-
ming (Hong et al., 2009; Kawamura et al., 2009) and down-
regulation of P53 could promote reprogramming and iPSC
generation (Okita et al., 2011). Cyclic pifithrin-a (P, CPFT-a)
is a transcriptional inhibitor of P53. Compared with P53
short hairpin RNA or dominant-negative P53 protein, inhi-
bition of P53 by CPFT-a is efficient and easy to control.
Because P53 plays an important role in safeguarding
genome stability, it is ideal to release its inhibition in newly
generated iPSCs after reprogramming. Here, to enable
efficient iPSC generation from hUCs with various prolifer-
ation capabilities, we optimized non-viral approaches for
hUC reprogramming. Firstly, we selected CPFT-a, a P53Cell Reports j Vol. 6 j 717–728 j May 10, 2016 j ª 2016 The Authors 717
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Table 1. Isolation UCs from Healthy Adults
No. of Samples Collected
No. of Samples with
Successful Isolation % UC Isolation
No. of UC Samples
with Low Growth Rate
% of UC Samples with
Low Growth Rate
Male 24 8 33 4 50
Female 21 5 24 2 40
Total 45 13 29 6 46inhibitor, and other SMs known to promote reprogram-
ming such as A-83-01, Chir, thiazovivin (T, Tzv), and
NaB, to form an SM cocktail. Aided by this SM cocktail
and another SM, PD0325901 introduced only at later stage
of reprogramming, the hUC reprogramming efficiency was
significantly enhanced, up to 170-fold. The highly efficient
reprogramming could be achieved in 2 weeks with the aid
of these SMs. Furthermore, we found that non-transfected
autologous hUCs can be used as feeder to overcome the cell
death caused by electroporation for the transfection of re-
programming genes. Upon these optimizations, successful
rates of generating viral-free iPSCs from hUCs with
different states were greatly improved.RESULTS
SM Treatment Enables iPSC Generation from Poorly
Proliferating hUCs
In our attempt to isolate hUCs from healthy adults or
different patients with disease such as type 1 diabetes,
type 2 diabetes, and other blood disorders, the successful
rate for obtaining expandable hUCs is about 30% (Tables
1 and 2). Osmolality (OSM) of urine samples is an impor-
tant index for successful hUCs isolation. We found that it
is usually difficult to obtain cells if the OSM of urine is
more than 598 mmol/l or less than 241 mmol/l. Further-
more, 50% of the successfully isolated hUCs are very poor
in proliferation and the efficiencies for iPSC generation
vary widely between different batches. For example, three
different batches of hUC cell lines (HM1-1, HM1-2, and
HM1-3) derived from the same person showed dramatically
different reprogramming efficiencies using episomal vec-
tors and the previously reported approaches (Yu et al.,
2009; Xue et al., 2013) (Figure 1A). During this reprogram-
ming process, RM medium (REGM + DMEM/high glucose
containing minimal essential medium [MEM] non-essen-
tial amino acids [NEAA], glutaMAX-1, and 10% fetal bovine
serum [FBS] 1:1; the combination of the three is referred to
as RM used for hUC culture) was used at the initial induc-
tion stage (days 2–9), while mTeSR1 (human embryonic
stem cell [hESC] culture medium) was used at later stage
to expand the reprogrammed cells (days 10–13). To observe
the morphological changes more clearly, we seeded an718 Stem Cell Reports j Vol. 6 j 717–728 j May 10, 2016appropriate number of transfected hUCs onto 24-well
plates at a density of 2.5 3 104 cells/well. As shown in Fig-
ure 1A, only HM1-2 at passage 2 (HM1-2-P2) produced
alkaline phosphatase (AP)-positive iPSC colonies. Consis-
tently, HM1-2-P2 showed the highest proliferation among
all examined cell lines (Figure 1B), suggesting that cell pro-
liferation is a critical factor for a successful iPSC generation.
The apoptosis rates were not significantly increased in
hUCs with higher passage number (Figure 1C), indicating
that the apoptosis of hUCs might not be the rate-limiting
event during reprogramming. It has been reported that
P53 was activated and served as a critical barrier during
reprogramming (Banito et al., 2009). We showed that the
P53 level increased with the passages of hUCs (Figure 1D),
suggesting that P53might also be a negative factor for hUC
reprogramming. To promote iPSC generation from poorly
proliferating hUCs we chose CPFT-a, an SM inhibitor for
P53, to suppress P53 during hUC reprogramming. We
firstly confirmed the effective suppression of P53 by
CPFT-a using western blot (Figure 1E). Then we showed
that with CPFT-a added in reprogramming medium, P53
was downregulated while the reprogramming efficiency
significantly improved (Figures 1F and 1G). In addition,
we tested other SMs that are known to promote reprogram-
ming in our hUC reprogramming system. To this end,
we finalized five SMs (A-83-01, CHIR99021, Tzv, NaB,
PD0325901) that could work with CPFT-a to promote
hUC reprogramming. During iPSC generation, we added
five SMs (A-83-01, Chir, Tzv, CPFT-a, NaB; i.e., ACTPN) at
the early stage (first 7 days) and added one more com-
pound, PD, at the later stage to expand the reprogrammed
iPSCs (Figure 1H). We named this strategy as plan B (Fig-
ure 3A). Based on this strategy, all hUCs described in Fig-
ure 1A could be reprogrammed into iPSCs (Figure 1I). These
data indicate that a combination of P53 inhibitor with
other SMs in reprogramming medium enables iPSC ge-
neration from hUCs that are otherwise difficult to be
reprogrammed.
We further characterized iPSCs generated with the re-
programming strategy plan B. Two iPSCs, HM1-iPS and
HF1-iPS, generated from healthy male and female adult
UCs were selected for further characterization. These two
iPSCs showed typical hESC morphology (Figures S1A and
S1B) and could be well expanded on Matrigel in mTeSR1
Table 2. Isolation of UCs from Patients with Diabetes and Blood Disorders
Disease Sex
No. of Samples
Collected
No. of Samples with
Successful Isolation % UC Isolation
No. of UC Samples with
Low Growth Rate
% of UC Samples with
Low Growth Rate
T1D male 6 4 67 3 75
female 3 2 67 0 0
total 9 6 67 3 50
T2D male 38 14 37 9 64
female 12 1 8 1 100
total 50 15 30 10 67
Blood disorders male 8 2 25 0 0
female 2 0 0 0 0
total 10 2 20 0 0
Overall total 69 23 33 13 57
T1D, type 1 diabetes; T2D, type 2 diabetes.medium. They maintained normal karyotype and AP posi-
tivity during multiple passaging (Figures S1C–S1F). PCR
analysis confirmed that these iPSC colonies had no trans-
gene expression or genomic integration (Figure S1G).
Typical pluripotency genes such as OCT4, SSEA4, TRA-1-
60, and TRA-1-81 were activated and detected by fluores-
cence-activated cell sorting (FACS) (Figure S1H). Moreover,
both OCT4 and NANOG promoters were demethylated in
these iPSCs based on the bisulfate sequencing analysis (Fig-
ure S1I). Upon injection intoNOD/SCIDmice, they formed
typical teratomas containing tissues from all three germ
layers (Figure S1J). In addition, we performed whole-
genome transcriptome analysis on iPSCs generated with
SMs. Four iPSCs from different batches of hUCs generated
with SMs showed little difference to hESCs, H1, in terms
of whole-genome transcriptome as well as expression of
selected pluripotent genes (Figures S1N–S1P). Taking all
the data together, we developed an optimized approach
to enable iPSC generation from poorly proliferating hUCs
and low reprogramming efficiency.
Minimizing SM Treatment during hUC
Reprogramming
Although adding SMs dramatically promotes hUC reprog-
ramming, too much SM treatment raised the concern
about generating more unwanted genetic or epigenetic
mutations (Wu et al., 2013). Thus, we sought to examine
whether some SMs could be removed during the whole re-
programming process. HM9, an hUC line isolated from a
healthymale, was used for the testing. The reprogramming
efficiency went down by about half when all six SMs were
withdrawn at later expansion stage (RM + 5M [ACTPN in
RM]-mTeSR1) and was more dramatically reduced uponwithdrawal at the early induction stage (RM-mTeSR1 +
6M [ACTPN + PD in mTeSR1]) (Figure 1J). These data indi-
cate that SM exposure at the early stage is much more crit-
ical for reprogramming. Therefore, for highly proliferating
hUCs, SMs could be removed at the later stage (RM + 5M-
mTeSR1, referred to as plan A) for iPSC generation (Fig-
ure 3A). We then examined whether we could further
remove some individual SMs at the early induction stage
to reprogram those highly proliferating hUCs. Two hUCs
with different proliferation rates, HF14-P3 (high) and
HF14-P5 (low), were used for further analysis. For HF14-
P5 with low proliferation, the reprogramming efficiency
was significantly reduced when C, N, or P was withdrawn,
while removal of A or T had little effect. These data sug-
gested that C, N, and P played important roles in reprog-
ramming poorly proliferating hUCs (HF14-P5) (Figure 1K).
For HF14-P3 with higher proliferation, the reprogramming
efficiency was significantly reduced when C was with-
drawn, but not A, T, or P (Figure 1L). Based on these find-
ings, we suggest that to reprogram highly proliferating
hUCs, N could be omitted, while for poorly proliferating
hUCs, A and T could be removed. In addition, we found
that SM treatment inhibited the genes reported to be
barriers to reprogramming (Qin et al., 2014) (Figure 1M),
which could be part of the mechanism for these SMs in
promoting hUC reprogramming.
Autologous UC Feeder Facilitates iPSC Generation
from hUCs
Another technical problem that usually occurs during iPSC
generation is cell death caused by electroporation for the
transfection of reprogramming factors. On many occa-
sions, the survival rate of hUCs after electroporation wasStem Cell Reports j Vol. 6 j 717–728 j May 10, 2016 719
Table 3. Six Small Molecules Used for Reprogramming
Abbreviation Small Molecule Function in Reprogramming Target References
A A-83-01 promotes reprogramming of human epidermal
keratinocytes using OCT4 and KLF4
()TGF-b(smad2) Yu et al., 2011; Zhu et al., 2010
C CHIR99021 combined with parnate results in the
reprogramming of human primary
keratinocyte transduced with OCT4 and KLF4
()GSK-3b Yu et al., 2011; Zhu et al., 2010
T thiazovivin ROCK inhibitor which dramatically improves
the reprogramming efficiency in the presence
of PD, Chir, A-83-01, and hLIF
()ROCK Yu et al., 2011
P cyclic pifithrin-a suppression or silencing of P53 significantly
increased the reprogramming efficiency of
human somatic cells
()P53 Hong et al., 2009; Kawamura
et al., 2009; Okita et al., 2011
N sodium butyrate enhanced miR302/367 cluster, histone H3
acetylation, promoter DNA demethylation,
and the expression of endogenous
pluripotency-associated genes
()HDAC Mali et al., 2010; Zhu et al., 2010;
Zhang and Wu, 2013;
PD PD0325901 PD serves as a selection strategy when
generating iPSCs from virally transduced
neural progenitor cells, and contributes to
stabilization of the iPSC state. Selectively
binds and inhibits MEK, which may result
in the inhibition of phosphorylation and
activation of MAPK/ERK and the inhibition
of tumor cell proliferation
()MEK-(+)MAPK/ERK Yu et al., 2011; Lin et al., 2009;
Zhu et al., 2010
See also Figure S2.less than 10% (Figure 2A), which is problematic for subse-
quent iPSC generation. In our experience, iPSC colonies
can be successfully generated if the number of surviving
cells is more than 2.5 3 104 cells/well of a 24-well plate,
while it usually fails if the surviving cells amount to fewer
than 1.5 3 104 cells/well (Figure 2B). To overcome the
reprogramming failure caused by low cell density, we re-
plated the transfected hUCs onto the untransfected autol-
ogous hUCs for reprogramming and iPSC generation.
T1D3, a hUC line isolated from a type 1 diabetes patient,
could not be reprogrammed to generate iPSCs using plan
B described above, due to low survival rate after electropo-
ration (Figure 2C, upper panel). However, typical iPSC
clones appeared upon plating the transfected hUCs onto
the autologous untransfected hUCs as feeders for reprog-
ramming (Figure 2C, lower panel and Figures S1K–S1P).
We termed this approach plan C (Figure 3A). Moreover,
we found that application of autologous hUC feeder also
dramatically enhanced the reprogramming efficiency of
hUCs, with higher passage number and poor proliferation
(Figure 2D). However, for hUCs with lower passage
numbers and good proliferation, including the hUC feeder
was not beneficial and even inhibited iPSC generation (Fig-
ure 2E), indicating that too many hUCs may compete with
the growth of reprogrammed cells. We also showed that720 Stem Cell Reports j Vol. 6 j 717–728 j May 10, 2016employing other cell lineages as feeders, such as human
foreskin cell and amniotic fluid cells, showed little effect
on hUC reprogramming (Figures 2F and 2G). In addition,
including the appropriate number of autologous hUC
feeders could substitute Matrigel during reprogramming,
which is helpful in developing a totally defined condition
for iPSC generation (Figure 2H).
Cell-Dependent Reprogramming Strategy for Banking
iPSC Lines
Banking human iPSCs from different genetic backgrounds
would be valuable for further studies on disease modeling
and drug screening as well as regenerative medicine.
Here, we summarized three reprogramming strategies for
reprogramming hUCs with various properties (Figure 3A).
For banking iPSCs, we selected a particular strategy to
generate hUC-derived iPSCs based on the proliferation
capability of the isolated hUCs. For example, we chose
plan A for hUCs with high proliferation and plan B for
those with moderate proliferation. Plan C can be used if
the survival rate of hUCs after electroporation is very low
(Figure 3A). To test these strategies, we chose a hUC line
with moderate proliferation to generate iPSCs using plans
A, B, and C, respectively, and found that plan C was the
best while plan B was better than plan A (Figures 3B and
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Figure 1. Cocktail of P53 Inhibitor CPFT-a and Other Small Molecules Improves Reprogramming Efficiency of UCs Isolated from
Individual Healthy Adults
(A) UCs reprogramming using RM-mTeSR1 without small-molecule cocktail. UCs HM1-1, HM1-2, and HM1-3 represent UCs collected from a
healthy male donor at passages (P) 2 and 5 and used for reprogramming (n = 3).
(B) Growth curves of UCs at passages 2 and 5 (n = 3).
(C) FACS analysis on cell apoptosis through the expression of annexin V and PI. The percentage of annexin V-positive cells was analyzed.
HM1 includes HM1-1, HM1-2, and HM1-3. Positive control was treated with 800 mM H2O2 for 4 hr.
(legend continued on next page)
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3C). Based on the selected strategy, wewere able to generate
iPSCs from most batches of the isolated hUCs that was
otherwise difficult to achieve using previously reported
methods (Figures 3D–3F). We also examined these strate-
gies in reprogramming other cell types, such as amniotic
fluid cells (AF1-P5) and mesenchymal stem cells (MSCs).
Our described approaches also enhanced iPSC generation
from AF cells or MSCs, albeit the overall reprogramming
efficiency of MSCs was much lower than that of AF cells
(Figures 3G and 3H). In summary, we developed a panel
of approaches to reprogram hUCs with different prolifera-
tion capabilities, potentially of value in banking human
iPSC lines from different genetic backgrounds.DISCUSSION
Generation of human iPSCs through a non-virus integra-
tion approach is usually slow and less efficient and thus
hampers its wider applications, particularly for banking
iPSCs from different genetic backgrounds and patients.
Cells isolated from human urine provide a convenient
and non-invasive way to obtain patient cells for iPSC
generation. However, we found that a high number of
isolated hUCs showed limited proliferation and were
difficult to reprogram for iPSC generation using the
non-viral approach. To generate iPSCs from hUCs with
low proliferation rates, we developed an optimized re-
programming process. Through application of SMs and
autologous untransfected hUC feeders to enhance reprog-
ramming, we were able to generate iPSCs from most
batches of hUCs, particularly for those poorly prolifer-
ating hUCs that were difficult to reprogram using other
methods. Our approaches would be valuable in banking
iPSC lines from individuals with different genetic
backgrounds.(D) The expression level of P53 tested by western blot. HF1 represents
used for qPCR. **p < 0.01 (n = 3).
(E) Effect of cyclic pifithrin-a, a P53 inhibitor, on P53 expression. UV, 8
as the negative control without UV treatment. CPFT-a, incubated for
(F) The expression level of P53 of UCs in the process of reprogrammin
(G) UCs reprogramming treated with CPFT-a. UCs, HM1-P3. ***p < 0.0
(H) Scheme of reprogramming plan B (R5 +5 M-mTeSR1 + 6M, ACTNP
mTeSR1 for proliferation stage).
(I) Reprogramming efficiency using plan B. UCs HM1-1, HM1-2, and H
(J) Reprogramming efficiency with small-molecule cocktail added at
(K) Role of single small molecule in RM + 5M for UCs with poor prolif
(L) Role of single small molecule in RM + 5M for UCs with good prolif
(M) The expression level of 14 known reprogramming barriers in UCs tr
****p < 0.0001 (n = 3).
Data were analyzed using a two-tailed Student’s t test. Error bars indic
a summary of small molecules used for reprogramming, see Table 3. F
722 Stem Cell Reports j Vol. 6 j 717–728 j May 10, 2016The role of SMs in aiding iPSC generation has been exten-
sively examined in different somatic cells, such as human
adult/fetal fibroblasts, mouse embryonic fibroblasts, and
human epidermal keratinocytes (Esteban et al., 2010;
Hou et al., 2013; Li et al., 2009; Lin et al., 2009; Mali
et al., 2010; Shi et al., 2008; Yu et al., 2011; Zhu et al.,
2010). Here, we re-examined the role of different SMs in
hUC reprogramming. We found that Chir and CPFT-a
significantly improved hUC reprogramming (p < 0.001),
while NaB showed moderate improvement (p < 0.05). In
contrast, A-83-01 and Tzv had a minimal effect when
they were used alone (Figure S2). PD0325901 has been
shown to suppress the growth of non-reprogrammed cells
and promote reprogramming when added at a later stage
(Shi et al., 2008). Consistently our results show that during
hUC reprogramming, adding PD0325901 at an early stage
inhibits reprogramming but at a later stage promotes re-
programming (Figures S3A–S3D). Among these six tested
SM, CPFT-a, a P53 inhibitor, has not been previously
reported to be used for reprogramming. P53 has been re-
ported to be a critical barrier during somatic cell reprogram-
ming (Marion et al., 2009) and also an important tumor
suppressor (Levine and Oren, 2009). For efficient reprog-
ramming, P53 is usually a considered target for suppression
during iPSC generation. In fact one of the reprogramming
factors, SV40LT, is known as a negative regulator of P53. In
addition, suppressing P53 through other biological ap-
proaches such as RNAi or even gene knockout promotes
reprogramming, but raises safety concerns regarding
genome instability due to the low activity of P53. There-
fore, considering that SV40LT, another negative factor for
P53, was already included for reprogramming, we mini-
mized the application of CPFT-a during hUC reprog-
ramming. Adding a low concentration of CPFT-a indeed
suppressed P53 expression and enhanced the final effi-
ciencies of iPSC generation during hUC reprogrammingUCs collected from a healthy female donor at passages 6 and 12 and
hr after UV ray treatment (15 s, 6000 mW/cm2).UV, RM functions
8 hr with 10 mM CPFT-a.
g. UCs, HF14-P5. **p < 0.01 (n = 3).
01 (n = 3).
was added in RM for induction stage and ACTNP + PD was added in
M1-3, at passages 2 and 5, were used for reprogramming (n = 3).
different stages. UCs, HM9-P3. *p < 0.05, **p < 0.01 (n = 3).
eration ability. UCs, HF14-P5. *p < 0.05 (n = 3).
eration. UCs, HF14-P3. *p < 0.05, **p < 0.01. (n = 6).
eated by RM + 5M normalized. UCs, HM1. **p < 0.01, ***p < 0.001,
ate the SD. Replicates were biological independent experiments. For
or the role of PD in reprogramming, see Figure S3.
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(Figures 1F and 1G), indicating a synergistic suppression of
P53with SV40LT. Another SM reported for enhancing iPSC
generation, NaB, did not show a significant effect in pro-
moting hUC reprogramming (Figure 1L). NaB was known
to activate the expression of miR302/367, which further
promotes reprogramming (Zhang and Wu, 2013). Liang
et al. (2010) reported that NaB facilitated reprogramming
only in the presence of exogenous c-Myc. For hUC reprog-
ramming, we replaced C-Myc with miR302/367 as reprog-
ramming factor, which might explain the less significant
effect of NaB on hUC-derived iPSC generation. Neverthe-
less, due to the variation in different batches of hUCs (Fig-
ure S2), it is still beneficial to includeNaB in the SM cocktail
when reprogramming hUCs with poor proliferation.
Another improvement of our optimized strategy is the
application of autologous hUC feeders to support iPSC gen-
eration. In most cases we found that if the number of sur-
viving cells after factor transfection was not sufficient, it
usually failed to generate iPSCs. To overcome this problem,
we plated the transfected hUCs onto the autologous non-
transfected cells for further reprogramming. Aided by the
feeder, wewere able to generate iPSCs from a very lownum-
ber of surviving hUCs. Based on our experience, in the
absence of Matrigel, if the cells reach confluence of be-
tween 80% and 100% at day 5 or 6 of reprogramming, we
will definitely obtain bona fide iPSC clones. However, we
found that during reprogramming, if the total number of
UCs is too high, the reprogramming efficiency decreases.
Thus, to reprogram UCs with a high growth rate, we need
to optimize the number of autologous UCs as feeder. Appli-
cation of a feeder to replace Matrigel as the extracellular
matrix for reprogramming is valuable in generating iPSCs
under conditions with no animal components. In sum-
mary, we described here optimized approaches for the gen-
eration of iPSCs from hUCs, particularly for those poorlyFigure 2. Autologous UC Feeders Facilitate Reprogramming of UC
(A) Survival rate of different UC samples after nucleofection. Each dot
and after nucleofection was calculated by cell count. UCs were collec
(B) Poorly proliferating UCs at low cell density (1.5 3 104 cells in on
**p < 0.01 (n = 3).
(C) UC T1D3-P4 with a low proliferation rate generated iPSCs with pla
(D) Optimization of the density of UC feeders for optimal reprogramm
based on UCs as initiating cells. UC, HM6-P5. **p < 0.01, ***p < 0.0
(E) Optimization the density of UC feeders for optimal reprogramming
on UCs as initiating cells. UCs, HM1-P3. *p < 0.05, **p < 0.01 (n = 3
(F) Human foreskin fibroblast cell (HFF1-P8) and amniotic fluid cell (
HF1-P4. **p < 0.01, ****p < 0.0001 compared with HF1-P7 (n = 3).
(G) Human foreskin fibroblast cell (HFF1-P8) and amniotic fluid cell (
HF1-P6. *p < 0.05 compared with HF1-P7 (n = 3).
(H) Substitution of Matrigel with autologous UC feeders on gelatin-c
Data were analyzed using a two-tailed Student’s t test. Error bars indica
characteristics of iPSCs generated with reprogramming strategies pla
724 Stem Cell Reports j Vol. 6 j 717–728 j May 10, 2016proliferating hUCs that are otherwise difficult to repro-
gram. Using these strategies, we were able to generate iPSCs
from almost 100% of different batches of isolated hUCs,
which are valuable for banking iPSCs from patients with
different genetic backgrounds.EXPERIMENTAL PROCEDURES
Ethical Statement
The individuals in this study have signed written informed con-
sent for donating UCs for stem cell generation. The experiments
involving human subject and animal research had been reviewed
and approved by the Institutional Review Board at Guangzhou In-
stitutes of Biomedicine and Health (GIBH) (no. 2010012). The
studies using human cells and mice have been approved by the
Human or Animal Subjects Oversight Committee of GIBH.Collection and Expansion of UCs
Onehundred and fourteen donorswere recruited for urine samples
with informed consent based on IRB approval (no. GIBH-IRB02-
2009002) of GIBH. The purposes and procedures for isolating urine
cells and generating stem cells were explained to donors in detail,
and questions, if any, were answered in full. We then obtained a
formal signed consent form and collected a total of 50–500 ml of
urine from each donor. UCs were collected as described previously
(Zhou et al., 2011, 2012). In brief, urine samples were collected at
the mid-stream from 114 individuals. Osmolarity pressure (OSM)
of each urine sample was tested and urine samples’ OSM between
241 mmol/l and 598 mmol/l were centrifuged to collect the exfo-
liated cells. The primary UCs were then processed and cultured
and passaged inmedium consisting of REBM (renal epithelial basal
medium; Lonza) medium containing SingleQuot Kit CC-4127
REGM (Lonza)/DMEM/high glucose (13) (Hyclone) containing
1003 MEM NEAA (Gibco), 1003 glutaMAX-1 (Gibco), and 10%
FBS (Hyclone) 1:1 (the combination of the three is referred to
as RM).s with Poor Proliferation Ability
represents a UC sample for reprogramming. The cell number before
ted from healthy adults and patients (n = 73).
e well of a 24-well plate) displayed low reprogramming efficiency.
n C. The iPSCs are indicated by a black circle. Scale bar, 500 mm.
ing of UCs with poor proliferation ability. The fold was calculated
01 (n = 3).
of UCs with good proliferation ability. The fold was calculated based
).
AF1-P6) as feeders for reprogramming of UCs at early passage. UCs,
AF1-P6) as feeders for reprogramming of UCs at late passage. UCs,
oated plate. UCs, HM4, HF1. *p < 0.05 (n = 3).
te the SD. Replicates were biological, independent experiments. For
n B and plan C, see Figure S1.
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The medium was the same as for Plan 
B, but cells were seeded on autolo-
gous UC feeders pre-coated or 
co-seeded with electroporated UCs.
Figure 3. Comparison of Plans A, B, and C on Reprogramming of UCs, Amniotic Fluid Cells, and Mesenchymal Stem Cells Collected
from Umbilical Cord Blood
(A) Scheme of plans A, B, and C for reprogramming. Growth curves of UCs were the same as shown in Figure 1B.
(B) AP staining assay of iPSCs induced from HM1-3-P3 used RM, plans A, B, and C (n = 2).
(C) The bona fide iPS clones induced by RM, plans A, B, and C. UCs, HM1-3-P3 (n = 2).
(D–F) Plans A, B, and C were used to construct an iPSC bank. UCs, HM3, T2D2, T2D9, T1D3, T2D1, T2D27, T1D4, T2D3, T2D4. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 3).
(legend continued on next page)
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Cell Proliferation Curves
UCs (20,000) were seeded per well (24-well plate). Three wells were
harvested every 24 hr to count the number of cells. The cell popu-
lations were analyzed using a two-tailed Student’s t test. Error bars
indicate the SD (n = 3).
iPSC Generation
UCs (53 105 to 13 106) were individualized by trypsin treatment
(0.05%trypsin/0.5mMEDTA,Gibco) andelectroporatedwith indi-
cated episomal plasmids using an Amaxa Basic Nucleofector Kit for
primary mammalian epithelial cells, program T-020 (Lonza). The
electroporated UCs were seeded onto P6 wells, and the next day
passaged to Matrigel (354277, Becton Dickinson) pre-coated P24
wells. In each nucleofection, 6 mg of pEP4EO2SET2K (Yu et al.,
2009) (contains OCT4, SOX2, SV40LT, and KLF4) and 4 mg of
pCEP4-miR-302-367 cluster (Liao et al., 2011) (contains miR-
302b, c, a, d, and miR-367) were used. The induced media during
reprogramming and proliferation were named plan A, plan B, and
plan C. The concentration of SMs was shown as follows: 0.5 mM
A-83-01 (SML0788-5MG, Sigma), 3 mM CHIR99021 (252917-06-9,
GuangzhouLauraBiotech), 0.5mMTzv (1226056-71-8,Guangzhou
Laura Biotech), 250 mM sodium butyrate (303410-100G, Sigma),
0.3 mM cyclic pifithrin-a (04-0040, Stemgent), and 0.5 mM
PD0325901 (Guangzhou Laura Biotech). plan A was RM at
days 0–1, RM + 5M at days 2–9, and defined medium mTeSR1
(STEMCELL) at days 10–13. plan B was RM at days 0–1, RM + 5M
at days 2–9, and mTeSR1 + 6M at days 10–17. The medium of
plan C was the same as for plan B, but cells were seeded on autolo-
gous UC feeders pre-coated or co-seeded with electroporated UCs.
Each medium was changed every other day. The iPSC colonies
were picked at around days 13–18 and cultured in mTeSR1 on
Matrigel. The culture medium was changed daily. The iPSCs were
passaged with 0.5 mM EDTA (25200-056, Gibco).
iPSC Characterization
PCR analysis of exogenous reprogramming factors and episomal
backbone integration, FACS analysis (OCT-3/4 antibody, Santa
Cruz Biotechnology sc-5279; anti-SSEA4 antibody, Abcam
AB16287; anti-TRA-1-81, Millipore MAB 4381; and anti-TRA-1-
60, Millipore MAB 4360). AP staining, karyotyping, and bisulfate
sequencing were performed as we described previously (Qin et al.,
2008; Wang et al., 2013). Specifically, we used NBT and BCIP
(GenView) for AP staining. The primers used for cloning, PCR
analysis, qPCR, and bisulfate sequencing were used according
to a previous report (Xue et al., 2013). Total RNA was extracted
using Trizol (Invitrogen) and reverse transcribed by oligo(dT) or
specific primers. qPCR was performed in triplicate with a
CFX96 machine (Bio-Rad) and SYBR Green Premix EX Taq Kit
(Takara) following the instructions by the manufacturer. Tera-
toma formation was done to examine the in vivo differentiation
potential of human iPSCs derived with the 6-SMs method. iPSCs(G) Amniotic fluid cells (AF1-P5) reprogramming using plans A, B, an
(H) Mesenchymal stem cells collected from umbilical cord blood (MSC-
in plan C (n = 3).
Data were analyzed using a two-tailed Student’s t test. Error bars ind
726 Stem Cell Reports j Vol. 6 j 717–728 j May 10, 2016grown on Matrigel in mTeSR1 were collected with EDTA treat-
ment, then resuspended by Matrigel and injected into hindlimb
muscles of 6-week-old immunocompromised SCID mice (one
6-cm dish with 50%–80% confluence per injection per mouse).
Two injections were performed for each iPSC clone. After
6–8 weeks, teratomas were obtained from all injections. The tera-
tomas were dissected and fixed in 4% paraformaldehyde (Jingxin
Biotechnology). Samples were embedded in paraffin and pro-
cessed with H&E staining in the Experimental Pathology Depart-
ment of GIBH.
Flow Cytometry Analysis
About 13 106 iPSCs were used for each staining. iPSCs were trypsi-
nized and fixed with 1% paraformaldehyde dissolved in PBS for
10 min at 37C. The cells were then washed with FACS buffer
(PBS containing 2% FBS) and resuspended in 90% ethanol for per-
meabilization by incubating 30 min on ice. After washing, cells
were sequentially incubated with primary and secondary antibody
for 30 min at 37C. Control samples were stained with iso-
type-matched control antibodies. The iPSCs were washed and
resuspended in FACS buffer and then processed for analysis on
FACSCalibur (BD).
RNA-Seq
Total mRNA was isolated from hUCs, iPSCs, and ESCs. RNA-seq li-
braries were constructed using the TruSeq RNA Sample Preparation
Kit v2 (Illumina). Libraries were sequenced using MiSeq Reagent
Kit v2. Hierarchical clustering of the RNA-seq data, heatmaps,
and scatterplots were generated using glbase (Hutchins et al.,
2014).
ACCESSION NUMBERS
The accession number for the RNA-seq data of iPSC and hUC re-
ported in this article is GEO: GSE79134. RNA-Seq data of ESCs
are available in Gene Expression Omnibus (GEO: GSE69797)
(Huang et al., 2015).
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